HAIC + tislelizumab + apatinib

**HAIC + tislelizumab + apatinib** is an investigational co-administration regimen for unresectable or advanced intrahepatic cholangiocarcinoma. In the registered phase II study, hepatic arterial infusion chemotherapy consisted of intra-arterial oxaliplatin and fluorouracil, combined with intravenous tislelizumab, an anti-programmed cell death protein 1 monoclonal antibody, and oral apatinib, a vascular endothelial growth factor receptor 2 inhibitor. The regimen is intended to combine locoregional cytotoxic exposure with immune-checkpoint blockade and antiangiogenic therapy. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05290116))

Brand names

AitanTevimbra

Other names

apatinib + HAIC + tislelizumabfluorouracil + oxaliplatin + tislelizumab + apatinibHAIC combined with tislelizumab and apatinibtislelizumab + apatinib + HAIC